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Although there has been a substantial decline in
lead exposure in the United States during the
past couple of decades (Pirkle et al. 1994),
mobilization of existing lead stored in bone
potentially represents an important endogenous
source of exposure. Specifically, it has been
hypothesized that lead may be mobilized from
skeletal stores during conditions of high bone
turnover, such as during menopause (Silbergeld
et al. 1988). Approximately 90–95% of the
total body burden of lead is retained in bone
(Barry 1975; Barry and Mossman 1970), where
the half-life can be several decades (Börjesson
et al. 1997; Gerhardsson et al. 1993; Nilsson
et al. 1991; Price et al. 1992; Rabinowitz et al.
1976). During menopause, calcium and other
minerals are mobilized from bone (Pounds
1984; Bronner 1992; O’Flaherty 1992;
Simons 1993). Lead is covalently bound in the
mineral matrix, apparently in close chemical
association with calcium and phosphate
(Wittmers et al. 1988). Furthermore, lead is
concentrated selectively according to the type
of bone, with higher accumulations in trabecu-
lar as opposed to cortical bone (Wittmers et al.
1988; Inskip et al. 1992; Lindquist et al.
1981). It has been estimated that up to 50% of
trabecular bone and 30% of cortical bone is
lost during a woman’s lifetime, particularly
during the early menopausal years (Lindquist
et al. 1981; Heaney et al. 1978; Riggs and
Melton 1986). Lead is mobilized from the
bone into the blood compartment. Lead in
blood can then be transferred to soft tissues,
including the central nervous system, where it
could affect cognitive and motor functions
(Landrigan et al. 1982; Ryan et al. 1987).
Age-adjusted data from the second
National Health and Nutrition Examination
Survey (NHANES II, 1976–1980; Silbergeld
et al. 1988), the Hispanics HANES
(HHANES, 1982–1984; Symanski and
Hertz-Picciotto 1995), and NHANES III
(1988–1994; Nash et al. 1998) showed higher
blood lead levels among postmenopausal
women compared with premenopausal
women. Similarly, blood lead levels were
higher in postmenopausal women compared
with premenopausal women in a subsample of
the Nurses Health Study (Korrick et al. 2002)
and two studies in Mexico City (Garrido
Latorre et al. 2003; Hernandez-Avila et al.
1998). However, these studies were all based
on cross-sectional data, and only two investi-
gations (Garrido Latorre et al. 2003; Korrick
et al. 2002) had any information on bone lead
concentrations.
This investigation represents a longitudi-
nal study with repeated measures of blood and
tibia lead and bone mineral density (BMD)
measurements among women undergoing sur-
gically induced menopause. In addition to
assessing whether there was any evidence of
increased endogenous lead exposure as a result
of the surgical menopause, we aimed to evalu-
ate the effects of BMD, estrogen replacement
therapy (ERT), serum ferritin, and endoge-
nous estrogen levels on changes in blood and
bone lead measurements.
Materials and Methods
The study population was recruited from
women ≥ 30 years of age who had a surgical
admission or discharge diagnosis of a bilat-
eral oophorectomy for a benign condition at
Mount Sinai Hospital during October 1994
through April 1999. Excluded were women
with preexisting neurologic or psychiatric
diseases and any medical condition that could
affect bone homeostasis. Also excluded were
women who were taking corticosteroids, thy-
roid hormone replacement, or antiseizure
medications. Women who had had no menses
within the previous 6 months or fewer than
nine menstrual periods within the past year
were considered to be postmenopausal and
were therefore not included. The ﬁnal study
population comprised 91 premenopausal or
perimenopausal women.
The study protocol included a baseline
visit before or shortly after surgery and follow-
up assessments at 6 and 18 months after
surgery. At the baseline visit, a structured
questionnaire was administered; 25 cc blood
was obtained for blood lead, serum ferritin,
and hormone analysis; tibia lead concentra-
tion was determined via 109Cd-based K shell
X-ray ﬂuorescence (XRF) analyses; and BMD
was measured by dual energy X-ray absorp-
tiometry (DXA). The 6-month visit included
all of the preceding measures except for the
BMD assessment. The 18-month assessment
was identical to the baseline evaluation. The
research protocol was approved by the institu-
tional review board of Mount Sinai Hospital,
and written informed consent was obtained
from all patients.
An attempt was made to obtain the baseline
assessment of each patient before surgery. This
was often not feasible because of the short lead
time for the surgical admission and the fact that
the decision to perform a bilateral as opposed to
a unilateral oophorectomy was frequently not
made until during the procedure. As a result,
58.2% had a baseline assessment before surgery,
and 41.8% had the baseline assessment within
2–29 days after the procedure.
Information on covariates, such as socio-
demographic characteristics; height and
weight; occupational and environmental 
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cal history, and use of medications including
ERT; physical activity, cigarette smoking, and
alcohol consumption, was obtained from the
questionnaire. Serum ferritin levels, which are
indicative of iron stores, were determined at
each visit because there is some evidence that
high ferritin levels are associated with lower
blood lead concentrations (Baghurst et al.
1987). Estradiol levels were assessed as an
indicator of endogenous estrogen levels. Levels
of follicle-stimulating hormone, which is a
marker of reproductive senescence, were also
assessed to verify that the patients were not
postmenopausal at the time of the surgery.
Blood lead was determined using graphite
furnace atomic absorption spectrophotome-
try with Zeeman background correction
(model 4100ZL; Perkin Elmer, Norwalk,
CT) using the method of Parsons (1992) at
the Mount Sinai Lead Laboratory. The lead
laboratory was certiﬁed by the Occupational
Safety and Health Administration (OSHA)
and participated in two proficiency testing
programs for blood lead (Centers for Disease
Control and Prevention and the Wisconsin
State Laboratory of Hygiene and College of
American Pathologists). OSHA certification
requires that proficiency tests come within
6 µg/dL of the target value (or all-method
mean) if that value is < 40 µg/dL or within
15% of the target (or all-method mean) if the
value is > 40 µg/dL. During a 1-year period
while these samples were being analyzed, the
accuracy was within 5% or on average
< 0.2 µg/dL deviation from target values for
48 proficiency test samples (analyzed in
masked fashion) across a wide range of values
(0–100 µg/dL). A subsample of triplet sam-
ples (baseline, 6-month, and 18-month speci-
mens) was run on the same day in the same
laboratory batch for 37 women.
The bone lead measurements were per-
formed on the anterior, mid-diaphysis of the
left tibia, which consists primarily of cortical
bone. BMD was measured for left radius/ulna,
left hip femoral neck, left hip trochanter,
whole left leg (which included both the tibia
and the femur), lumbar spine, and whole
body. The measurements were obtained with
a Hologic QDR 2000 DXA densitometer
(Hologic, Bedford, MA) at the Bone
Densitometry Laboratory at Mount Sinai
Hospital. The scans were analyzed according
to computer software protocols for each site
provided by the manufacturer.
The XRF method sometimes produces
negative results for low bone lead concentra-
tions. This is because the method produces an
unbiased (Todd et al. 2002) point estimate of
the true concentration that oscillates, because
of measurement uncertainty, around the true
bone lead concentration. Other researchers
(Hu et al. 1998; Kim et al. 1995) have exam-
ined the retention of the negative values in the
analyses of data from epidemiologic studies
and have recommended the retention of all
data because alternative procedures (e.g., set-
ting the negative values to zero or to half the
value of the detection limit) introduce bias.
It is not possible to assign a speciﬁc detec-
tion limit to the XRF measurements. Each
lead X ray (and the coherent scatter) peak of
each in vivo bone lead measurement spectrum
has a detection limit (deﬁned in any one of a
number of ways). There is therefore no single
spectrum-based detection limit value for an
individual bone lead measurement. Further-
more, there is an “instrumental detection
limit,” which is usually superior to the more
realistic method detection limit. In addition,
there is a “system performance level” (Todd
et al. 1993) and other detection limit deﬁni-
tions described by the International Union on
Pure and Applied Chemistry (Todd et al.
2001, 2002). The XRF measurement
uncertainty could be used to establish a degree
of confidence in the lead concentration, but
those uncertainties have been shown to under-
estimate the standard deviation of repeated
measurements (Todd et al. 2001). Never-
theless, most of the tibia lead levels in this
study could be described as at or near the
method detection limit.
Because tests of normality showed that
the blood lead and tibia lead values were not
normally distributed (Shapiro-Wilk’s test,
p < 0.0001 and < 0.03, respectively), medians
are presented. The distributions of blood and
tibia lead levels were evaluated by Wilcoxon
rank sum test or, if there were more than two
categories, the Kruskal-Wallis test. Covariates
that were either categorical or continuous
were assessed by chi-square or Student’s
t-test, respectively. Relationships between
BMD and blood or tibia lead concentrations
were evaluated by Spearman’s correlation
coefficient. Changes in blood and bone lead
levels from baseline to 6 months, baseline to
18 months, and from 6 to 18 months were
evaluated by the Wilcoxon signed rank test.
Changes in blood and tibia lead levels
adjusted for covariates were evaluated with
multiple linear regressions.
Results
The study population consisted of 91 pre-
menopausal and perimenopausal women
≥ 30 years of age who were scheduled to
undergo a bilateral oophorectomy for a benign
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Table 1. Baseline median blood and tibia lead levels according to sociodemographic and lifestyle charac-
teristics among 91 women with a surgical menopause, Mount Sinai Hospital, 1994–1999.
Blood lead Tibia lead
Characteristic Median (µg/dL) No. p-Valuea Median (µg/g) No. p-Valuea
Age (years)
30–44 2.1 14 2.4 12
45–49 2.5 47 5.7 46
50–54 2.7 28 0.39 7.6 26 0.32
Race/ethnicity
White 2.6 55 5.7 50
African American 2.1 19 7.5 18
Hispanic 2.4 12 7.2 13
Asian 2.6 3 0.61 6.0 3 0.44
Education
Less than high school 3.4 9 4.4 9
High school graduate 2.5 12 8.6 12
Some college 2.0 19 6.1 18
College graduate 2.6 47 0.39 5.6 45 0.33
BMI (kg/m2)
< 25 2.6 43 6.3 40
25–29.9 2.2 24 6.7 24
> 30.0 2.1 20 0.59 4.5 20 0.49
Cigarette smoking
Never 2.2 40 4.4 39
Ex-smoker 2.5 31 7.1 28
Current 3.4 15 0.14 11.4 16 0.02
Alcohol consumption (drinks/week)
0 1.9 42 3.4 42
1–6 2.6 35 7.6 35
> 7 3.5 9 0.001 9.5 9 0.03
Coffee consumption
0 2.1 22 3.3 23
1–2 2.6 40 7.5 38
> 3 2.7 15 0.63 7.1 14 0.28
ERT at 6 months
No 3.8b 15 10.4b 15
Yes 3.0 56 0.15c 5.8 55 0.11c
ap-Value is based on the Kruskal-Wallis test, unless otherwise indicated. bMedian blood and tibia lead levels at 6 months
after oophorectomy. cp-Value is based on the Wilcoxon rank sum test.condition at Mount Sinai Hospital during
October 1994 through April 1999.
Among the 91 women who enrolled in the
study, 71 completed the 6-month visit and
63 completed the 18-month visit. The age dis-
tribution of the 91 women was as follows:
15.4% 30–44 years of age, 53.9% 45–49 years
of age, and 30.8% 50–54 years of age. With
respect to race/ethnicity, 52.8% were white,
16.5% were African American, 9.9% were
Hispanic, and 2.3% were Asian. The partici-
pants were generally well educated: almost
70% had received college or higher education.
Regarding reproductive characteristics, 67.4%
had previously been pregnant and 56.2% had
previously delivered a live birth.
The proportion of women who reported
ERT use was 78.9% at 6 months postsurgery
and 77.8% at 18 months. The proportion of
ERT users who were taking a dose of
0.625 mg was 83.9% at the 6-month
follow-up and 74.5% at the 18-month assess-
ment. Among the users, 80.8% had stayed on
ERT for the period between the surgery and
the 6-month visit, and 53.0% had remained
on ERT during the period between surgery
and the 18-month visit. Current smokers
comprised 18.7% of the women, and 50.5%
reported consuming one or more alcoholic
drinks per week. Those who were lost to
follow-up were less well educated (p = 0.02)
and had a marginally higher body mass index
(BMI; p = 0.06) than did those who com-
pleted the follow-up visits. Other characteris-
tics did not differ between the two groups.
Furthermore, there was no signiﬁcant differ-
ence in blood lead levels at baseline for those
who were lost to follow-up compared with
those who remained in the study, although the
former group had a somewhat higher blood
lead level (3.1 µg/dL vs. 2.4 µg/dL; p = 0.23).
The median blood lead (2.5 µg/dL; range,
0.3–11.7 µg/dL) and tibia lead (6.0 µg/g bone
mineral; range, –22.2 to 36.4 µg/g) levels were
low at baseline. The median blood lead levels
were not signiﬁcantly different for those who
had the blood drawn before (2.2 µg/dL) as
opposed to after the surgery (2.6 µg/dL, p =
0.65). There were no signiﬁcant differences in
median blood lead levels or changes in the
blood lead levels over time when the triplicate
samples that were analyzed in the same batch
were compared with the samples analyzed in
separate batches. Table 1 presents the median
blood lead and tibia lead levels according to
selected sociodemographic and lifestyle charac-
teristics. A signiﬁcant positive association was
observed between number of alcoholic drinks
per week and median blood lead level. There
was some suggestion that blood lead levels
increased with age, decreased with increasing
BMI, and were lower for women who had
never smoked and those who were on ERT at
6 months, but none of these results was
statistically signiﬁcant. The blood lead levels
for the four racial/ethnic groups were similar.
No association was seen for parity (data not
shown).
With respect to tibia lead, signiﬁcant posi-
tive associations were observed both for current
cigarette smoking and the number of alcoholic
drinks per week. Tibia lead levels tended to
increase with age, as expected, and tended to
be lower for those on ERT at 6 months. The
tibia lead levels were slightly higher for African
Americans and Hispanics compared with
whites or Asians.
Assessment of other potential lead-related
variables such as occupations, hobbies, and
residential characteristics (e.g., peeling paint)
revealed no significant findings, although
women who reported a hobby involving
potential lead exposure, such as making jew-
elry or stained glass, had slightly higher blood
lead levels than did those who had no such
hobby (Table 2). The increased blood lead
levels for those who exercised on a regular
basis (> 1 hr/week) is difﬁcult to understand,
because bone turnover is generally less in
women who exercise (Wolff et al. 1999).
Women who had ever used herbal medicines
had a borderline significant elevated blood
lead level. Apart from the higher tibia lead lev-
els among women who reported a history of
hyperthyroidism, no other signiﬁcant ﬁndings
were observed with respect to characteristics
potentially related to tibia lead levels.
As expected, signiﬁcant negative declines
from the baseline to the 18-month BMD
assessments were seen for the lumbar spine
(paired t-test, p < 0.0001), the left hip femoral
bone (p = 0.004), and the left hip trochanter
(p = 0.005). The decline was particularly
marked for the lumbar spine for those who
had not been taking ERT, but a significant
decrement at this site did occur even for those
who had used ERT (p = 0.003). There was
only a slight and nonsignificant (p > 0.05)
drop in the left whole-leg BMD between the
baseline and 18-month follow-up assessment,
which was limited to those who were not on
ERT. However, because bone lead was mea-
sured in the left tibia, adjustment for BMD
was only based on the left leg. No signiﬁcant
correlations (based on the Spearman correla-
tion coefficient) were seen between left-leg
BMD and blood lead values either at baseline
or the 18-month follow-up or the change in
blood lead levels. With respect to the correla-
tion with tibia lead concentrations, there was a
significant positive relationship between the
left-leg BMD at baseline and the change in
tibia lead between 0 baseline and 6 months
(rs = 0.31, p = 0.02) but no correlation at the
18-month follow-up.
Table 3 shows the median blood and tibia
lead levels at baseline and at the 6-month and
18-month follow-up visits. Two women had no
blood lead determinations at baseline, and seven
women did not have a tibia lead assessment at
Article | Blood and tibia lead changes during menopause
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Table 3. Median blood and tibia lead levels at baseline, 6 months, and 18 months after oophorectomy by
ERTstatus among 91 women with a surgical menopause, Mount Sinai Hospital, 1994–1999.
Blood lead (µg/dL) Tibia lead (µg/g)
Follow-up period Median (range) No. Median (range) No.
All women 
Baseline 2.5 (0.3–11.7) 89 6.1 (–22.2–36.4) 84
6 months postsurgery 3.2 (0.4–12.0) 71 6.8 (–14.2–29.0) 70
18 months postsurgery 3.1 (0.5–9.1) 63 5.8 (–15.4–24.2) 62
Women on ERT
6 months postsurgery 3.0 (0.4–12.0) 56 5.8 (–14.2–24.3) 55
18 months postsurgery 3.1 (0.5–9.1) 49 4.2 (–15.4–24.2) 46
Women not on ERT
6 months postsurgery 3.8 (1.3–11.6) 15 10.4 (–6.9–29.0) 15
18 months postsurgery 3.2 (1.6–6.7) 14 6.9 (–4.0–19.9) 16
Table 2. Baseline median blood and bone lead levels according to other potential lead-related character-
istics among 91 women with a surgical menopause, Mount Sinai Hospital, 1994–1999.
Blood lead Bone lead
Characteristic Median (µg/dL) No. p-Valuea Median (µg/g) No. p-Valuea
Ever had lead-related hobby
No 2.1 40 5.2 38
Yes 2.6 44 0.12 7.6 43 0.53
History of hyperthyroidism
No 2.5 84 5.7 80
Yes 3.9 3 0.32 13.1 4 0.02
Physical exercise (> 1 hr/week)
No 2.1 28 4.7 27
Yes 2.6 56 0.04 6.9 54 0.21
Ever used herbal medicines
No 2.3 51 6.6 50
Yes 2.6 31 0.05 4.8 29 0.95
ap-Value based on Wilcoxon rank sum test.baseline. The sample sizes for the 6-month
and 18-month assessments are also given in
Table 3. Because not all women participated
in the 6-month and 18-month follow-up
assessments, changes in individual blood and
tibia lead levels are of greater relevance.
Table 4 summarizes the median changes over
the follow-up period. It may be seen that
median blood lead levels increased signifi-
cantly during the ﬁrst 6 months but did not
change significantly between 6 and
18 months postsurgery. Although the increase
during the first 6 months was greater for
women who were not on ERT, both women
with and without ERT experienced signifi-
cant increases. Similar changes were observed
for the tibia lead concentrations for all
women, but none of the changes was statisti-
cally significant. The tibia lead changes
according to ERT status are more difﬁcult to
interpret. There was a marginal decline in
tibia lead concentrations between 6 and
18 months for women who took ERT, but
not for those who did not take ERT. It
should be noted that some of these results
may reﬂect the different sample sizes.
Assessment of Spearman correlation coefﬁ-
cients between the change in blood lead and
tibia lead showed a borderline signiﬁcant result
for the change in blood lead and tibia lead
between baseline and 18 months (rs = –0.26,
p = 0.05). The rs for the change in blood and
tibia lead between 6 and 18 months was 0.22
(p = 0.10). Because the correlations went in
the opposite directions, these ﬁndings are not
easily interpretable.
Multiple regression analysis was used to
further explore the significant increase in
blood lead levels between baseline and
6 months postsurgery. Variables that were
considered included blood lead at baseline,
alcohol consumption, estradiol and serum fer-
ritin levels at 6 months, tibia lead adjusted for
BMD of the left leg at baseline, and change in
tibia lead between baseline and 6 months
adjusted for BMD. The results are summa-
rized in Table 5. The r2 for this model was
0.22. It may be seen that the endogenous level
of estradiol at 6 months, the BMD-adjusted
tibia lead level at baseline, and the change in
BMD-adjusted tibia lead level between base-
line and 6 months were signiﬁcant predictors
of the change in blood lead between baseline
and 6 months. Blood lead at baseline was not
significant but was included in the model
because exclusion of this variable resulted in a
borderline signiﬁcance for estradiol (p = 0.06).
No significant interaction was observed
between ERT use and baseline tibia lead level
adjusted for BMD in this model (p = 0.38).
Discussion
Despite the dramatic decline in environmental
lead exposure that has occurred in the United
States since the 1980s, certain subgroups, such
as poor inner-city residents and minorities,
remain more likely to have elevated levels of
blood lead. Pregnant and lactating women
(Gulson et al. 2003; Tellez-Rojo et al. 2002)
and those undergoing menopause (Nash et al.
1998) have been identified as additional
groups who may be at risk for increased blood
lead levels because of potential lead mobiliza-
tion during conditions of high bone turnover.
To date, however, there are no published
prospective studies that have assessed blood
lead, bone lead, and BMD changes during
these conditions. Possible increases in levels of
blood lead during menopause are of concern
because studies of adults have shown neuro-
cognitive deficits (Muldoon et al. 1994;
Payton et al. 1998) and increased blood pres-
sure (Nash et al. 2003; Symanski and Hertz-
Picciotto 1995) even at relatively low blood
lead levels.
Our data suggest a slight but significant
increase in blood lead between baseline and
6 months after a bilateral oophorectomy. This
increase was evident both for those on ERT
and those who were not on ERT, although the
increase was greater for the latter group. No sig-
niﬁcant changes in blood lead levels were seen
between 6 and 18 months postsurgery. With
respect to tibia lead concentrations, there was
some suggestion of an increase between baseline
and the 6-month follow-up for those who were
not on ERT therapy and a decline between
6 and 18 months for those who were on ERT
therapy. Thus, these ﬁndings do not point to
any substantial lead mobilization during
menopause. The fact that close to 80% of the
women were on ERT postsurgery may explain
the ﬁndings because ERT reduces bone resorp-
tion (Prestwood et al. 2000). Alternatively, cur-
rent bone lead concentrations may be
sufﬁciently low to result in the release of only
small amounts of lead into the bloodstream.
Previous studies on the effects of ERT on
blood and tibia lead levels are not entirely con-
sistent. A small cross-sectional study of blood
lead concentrations among postmenopausal
women either on ERT or calcium supplemen-
tation found that ERT may reduce the release
of lead from bone (Webber et al. 1995).
However, this was evident only for cortical
(tibia) and not trabecular (calcaneus) bone,
even though trabecular bone is thought to be
more sensitive to estrogen declines than is cor-
tical bone. Furthermore, ERT had no effect on
blood lead concentrations in the latter study.
Analysis of a subgroup from the Nurses’
Health Study (Korrick et al. 2002) found
higher blood lead levels in postmenopausal
women who were not taking estrogens than
either premenopausal women or post-
menopausal women who were using ERT.
Bone lead was positively associated with blood
lead only among postmenopausal women who
were not using ERT, and this was true both for
trabecular (patella) and cortical (tibia) bone
lead. A Mexican cross-sectional osteoporosis-
screening study reported that trabecular bone
lead (patella) was an important predictor of
blood lead in postmenopausal women both for
those with a natural or surgical menopause
(Garrido Latorre et al. 2003). Users of ERT
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Table 4. Median changes in blood and tibia lead levels during the follow-up period by ERT status among
91 women with a surgical menopause, Mount Sinai Hospital, 1994–1999.
Blood lead (µg/dL) Tibia lead (µg/g)
Median change Median change
Follow-up period (range) p-Valuea No. (range) p-Valuea No.
All women
0–6 months 0.4 (–2.0–9.6) < 0.0001 71 1.8 (–33.3–26.3) 0.22 69
6–18 months –0.1 (–7.6–3.9) 0.36 60 –2.2 (–18.6–22.2) 0.16 58
0–18 months 0.3 (–6.2–4.7) 0.06 63 –0.4 (–34.0–31.3) 0.86 62
Women on ERT postsurgery
0–6 months 0.3 (–2.0–4.4) 0.003 56 0.8 (–33.3–26.3) 0.59 55
6–18 months –0.1 (–7.6–3.9) 0.62 46 –2.8 (–18.6–22.2) 0.06 42
0–18 months 0.2 (–6.2–4.7) 0.16 49 0.1 (–34.0–31.3) 0.86 46
Women not on ERT
0–6 months 0.7 (–0.6–9.6) 0.008 15 5.0 (–10.5–19.7) 0.08 14
6–18 months –0.2 (–2.6–2.1) 0.31 14 2.2 (–14.0–14.9) 0.72 16
0–18 months 0.4 (–1.8–2.2) 0.21 14 –0.8 (–22.4–7.4) 0.49 16
ap-Value is based on the Kruskal-Wallis test.
Table 5. Multivariate model of blood lead changes between baseline and 6 months postsurgery among
91 women with a surgical menopause, Mount Sinai Hospital, 1994–1999.
Parameter
Variable estimate SE p-Valuea Partial r2
Intercept 1.36 0.58 0.02 —
Endogenous estradiol level at 6 months –0.01 0.01 0.03 0.09
Blood lead at baseline –0.17 0.12 0.16 0.04
Tibia lead at baselineadjusted for BMDb 0.07 0.03 0.008 0.13
Change in tibia lead at 0–6 months adjusted for BMDb 0.06 0.02 0.01 0.12
aBased on Student’s t-test. bTibia lead concentration multiplied by mean left-leg BMD. also had lower blood lead levels than did
nonusers in this study. In contrast, another
Mexican study found significantly higher
blood lead values in women with a natural
compared with a surgical menopause but no
difference according to ERT use (Hernandez-
Avila et al. 2000). Analysis of NHANES III
data for 1988–1994 showed lower blood lead
levels among postmenopausal women who
were current ERT users compared with past or
never users (Nash et al. 1998). Two studies
that also assessed BMD found no association
between BMD and blood lead values (Garrido
Latorre et al. 2003; Muldoon et al. 1994).
With respect to other correlates of blood
lead levels, positive associations have been
reported with increasing age (Hernandez-Avila
et al. 2000; Korrick et al. 2002; Muldoon et al.
1994; Weyermann and Brenner 1997), ciga-
rette smoking (Muldoon et al. 1994;
Weyermann and Brenner 1997), and alcohol
consumption (Korrick et al. 2002; Muldoon
et al. 1994; Weyermann and Brenner 1997).
Alcohol consumption was signiﬁcantly associ-
ated with increased blood lead levels in our
data, and nonsigniﬁcant positive trends were
evident for age and cigarette smoking. Use of
herbal remedies has been previously linked to
lead poisoning (Centers for Disease Control
and Prevention 1993; Markowitz et al. 1994).
In the study by Muldoon et al. (1994) of
women 65–74 years of age, moderate physical
activity was related to decreased blood lead val-
ues, but more strenuous activity was associated
with increased lead levels. We observed higher
blood lead values among women who exercised
> 1 hr/week, but our numbers were too small
to detect a dose–response relationship.
Only limited data are available on charac-
teristics inﬂuencing bone lead concentrations.
In a study of tibia lead concentrations, Kosnett
et al. (1994) reported positive associations with
age and cigarette smoking and a negative rela-
tionship with a history of lactation. Korrick
et al. (2002) found that older age and lower
parity were associated with higher tibia lead
but only age was related to patella lead levels.
We similarly found a signiﬁcant positive associ-
ation between tibia lead and cigarette smoking
and a positive trend with age. In addition, alco-
hol consumption signiﬁcantly increased bone
lead concentration. A history of hyperthy-
roidism was also a signiﬁcant predictor in our
study. Hyperthyroidism, which can cause bone
turnover (Goldman et al. 1994), would, how-
ever, be expected to be related to higher blood
but not bone lead levels.
Because there were signiﬁcant declines in
BMD for the lumbar spine, left hip femoral
neck, and left hip trochanter (but not in the left
leg or the radius/ulna), there is evidence of bone
turnover in this study population. However,
the possibility that a release of lead from bone
with subsequent redeposition cannot be 
discounted because tibia lead concentrations
did not change signiﬁcantly over the follow-
up period. Nevertheless, tibia bone lead con-
centrations were adjusted for left-leg BMD in
the final model. Another limitation of this
study is the fact that the whole-leg BMD
rather than just the tibial shaft BMD was
measured. Because both the tibia and the
femur primarily consist of cortical bone, mea-
surement of the whole leg should not have
had any major effect on our results.
Conclusion
We observed a small but significant increase
in blood lead between the baseline assess-
ment and the 6-month postsurgical visit, par-
ticularly for women who were not on ERT
after the surgical menopause. However, no
significant changes were observed for the
period between 6 and 18 months, nor were
there any significant changes in tibia lead
concentrations postsurgery. Thus, these data
do not support the hypothesis of substantial
lead mobilization from cortical bone during
menopause.
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